NEWS IN BRIEF

WuXi Biologics breaks ground on $240m manufacturing site near Beijing

By Flora Southey contact

- Last updated on GMT

WuXi Biologics' Biologics Center of Excellence (MFG8) in Shijiazhuan, China
WuXi Biologics' Biologics Center of Excellence (MFG8) in Shijiazhuan, China

Related tags: Wuxi biologics, China, CDMO

Construction has started at WuXi Biologics’ eighth drug substance manufacturing facility, which CEO Chris Chen says will enable the CDMO to “develop and manufacture biologics more cost effectively”.

Contract development and manufacturing organisation (CDMO) WuXi Biologics announced last week it has broken ground on its Biologics Manufacturing Center of Excellence (MFG8) in Northern China’s Hebei province.

The $240m (€203m) facility will house process development labs, 5,000L bioreactor capacity for clinical manufacturing, and 48,000L bioreactor capacity for commercial manufacturing.

According to the firm, the plant will serve both Chinese and global clients, and be built to meet current good manufacturing practice (cGMP) standards of the US, the European Union, and China. Operations are expected to begin in 2020.

“We are pleased to break ground today and look forward to the operations of this new Biologics Center,” ​said Chris Chen in a statement.

“This facility will enable WuXi Biologics to develop and manufacture biologics more cost effectively as well as to provide a robust supply chain network for our global partners, and ultimately to benefit patients worldwide,” ​he added.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us

Products

View more

Webinars